Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
Details : The collaboration focuses on the discovery of RNA therapeutics for sensorineural hearing loss. Rznomics will conduct early research, while Lilly will assume further development and commercialization.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration